BCLS Fund III Investments, LP

Overview

• HeadquartersBoston, United States²
• Legal formLimited Partnership²
• Kind of organizationLimited partnership²
• LEI254900FG58L5E6UH2565²
• StatusActive²
• LEI statusIssued and current²
• Registered addressC/O Maples Fiduciary Services (Delaware) Inc., 19807 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 6289951²

See how the biggest companies compare on our leaderboards

Corporate structure

BCLS Fund III Investments, LP sits at the top of its group. 6 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); stakes of 5% or more it reported on Schedules 13D and 13G (5 companies). Each entity in the chart links to its source.

Timeline

1. Oct 7, 2021Founded BCLS Fund III Investments, LP is founded²

Filings

9 filings to the SEC since October 2021: 9 other. The latest 9:

1. Aug 31, 2026N-PX EDGAR
2. Aug 14, 202613F-NT EDGAR
3. May 15, 202613F-NT EDGAR
4. Feb 17, 202613F-NT EDGAR
5. Nov 14, 202513F-NT EDGAR
6. Aug 29, 2025N-PX EDGAR
7. Aug 14, 202513F-NT EDGAR
8. May 15, 202513F-NT EDGAR
9. Feb 14, 202513F-NT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

BCLS Fund III Investments, LP has told the SEC it owns more than 5% of 5 companies, latest first (Schedules 13D and 13G).

• ADARx Pharmaceuticals, Inc.SCHEDULE 13G Oct 1, 2026³
• Heartflow, Inc.SCHEDULE 13G/A Nov 14, 2025 to Aug 14, 2026⁴
• Cidara TherapeuticsSCHEDULE 13G/A Jul 29, 2024 to Feb 17, 2026⁵
• Magenta TherapeuticsSCHEDULE 13G/A Feb 2, 2024 to Nov 14, 2025⁶
• Upstream Bio, Inc.SC 13G Oct 18, 2024⁷